Inhibrx Rg-Ai
Clinical‑stage biopharma advancing a portfolio of tetravalent and hexavalent biologic oncology agents—e.g., INBRX‑109 targeting death‑receptor‑5 in metastatic chondrosarcoma and INBRX‑106 targeting OX40 across solid tumors—with Phase 1 programs poised for rapid progression.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 156
- HQ: La Jolla
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.